Zyclara approved in the EU

Meda announced today that the European Commission (EC) has granted marketing
authorization for Zyclara in the European Union. Zyclara (imiquimod 3.75% cream)
is a patented product for the treatment of actinic keratosis. The approval is
valid in all EU countries.

"Skin cancer is increasing and it is important to develop and improve the
treatment of actinic keratosis. Zyclara is unique since it can treat large areas
of the skin", said Anders Lönner, CEO of Meda AB.

About Zyclara and actinic keratosis
Actinic keratosis (AK), early skin carcinoma in situ is an under-diagnosed and
under-treated disease and the number of affected patients is increasing. There
is a close regional coexistence of invisible (subclinical AK lesions) as well as
clinical visible AK lesions on areas of sun exposed skin - a phenomenon which is
called field cancerization.

Zyclara is to date the first clinically proven treatment option which can detect
and eliminate subclinical as well as clinical AK lesions on large areas of the
skin. Zyclara has shown in a large clinical development program to be an
effective therapy in eliminating both kinds of AK lesions and with low
recurrence rate.

For further inquiries, please contact:
Anders Larnholt, Vice President Corporate Development & IR      ph: +46 709
-458 878

MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in 120 countries worldwide and the company is represented by
its own organizations in 50 countries. The Meda share is listed under Large Cap
on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit
www.meda.se.

Forward-looking statements
This press release is not an offer to sell or a solicitation to buy shares in
Meda. This press release also contains certain forward-looking statements with
respect to certain future events and Meda’s potential financial performance.
These forward-looking statements can be identified by the fact that they do not
relate only to historical or current facts, and may sometimes include words such
as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”,
“forecast”, “believe” or other words of similar meaning. These forward looking
statements reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to a number of risks
and uncertainties. In the event such risks or uncertainties materialize, Meda’s
results could be materially affected. The risks and uncertainties include, but
are not limited to, risks associated with the inherent uncertainty of
pharmaceutical research and product development, manufacturing and
commercialization, the impact of competitive products, patents, legal
challenges, government regulation and approval, Meda’s ability to secure new
products for commercialization and/or development and other risks and
uncertainties detailed from time to time in Meda AB’s interim or annual reports,
prospectuses or press releases. Listeners and readers are cautioned that no
forward-looking statement is a guarantee of future performance and that actual
result could differ materially from those contained in the forward-looking
statements. Meda does not intend, nor undertakes, to update any such forward
looking statements.